GlaxoSmithKline (GS71) Price & Analysis
GS71 Stock Chart & Stats
- Day’s Range
- CHF 26.12 - CHF 26.12
- 52-Week Range
- CHF 26.12 - CHF 26.12
- Previous Close
- CHF 26.12
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- CHF 82.08B
- Enterprise Value
- CHF 94.96B
- Total Cash (Recent Filing)
- CHF 2.96B
- Total Debt (Recent Filing)
- CHF 23.70B
- Price to Earnings (P/E)
- 17.2
- Beta
- N/A
- Next Earnings
- Feb 03, 2027
- EPS Estimate
- 0.31
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- 3.66%
Bulls Say, Bears Say
Bulls Say
Specialty Medicines Growth
Broad-based specialty-medicine growth across HIV, respiratory and oncology reduces reliance on a single product and supports a stronger long-term mix. Double-digit performance from several launches also indicates meaningful commercial traction for GSK’s differentiated portfolio.
Pipeline And Launch Momentum
The sharp acceleration in late-stage development expands GSK’s opportunity to replenish and diversify future revenue. Multiple approvals, launches and positive clinical readouts create several potential growth drivers rather than depending only on established medicines.
Cash Generation And Profitability
Strong operating cash flow and free cash flow give GSK internal funding for research, launches, business development and shareholder distributions. High profitability and recent cash-flow growth provide useful resilience while the company invests heavily in its pipeline.
Bears Say
Leverage And Interest Burden
GSK’s meaningful debt load reduces financial flexibility and makes earnings more sensitive to refinancing costs. Higher interest expense, including financing related to Nuvalent, can absorb cash that could otherwise support research, acquisitions or debt reduction.
Rising Investment And Restructuring Costs
Accelerated oncology investment may strengthen the pipeline, but the near-term cost burden is substantial and is growing faster than sales. Higher R&D and restructuring charges can limit operating leverage and make earnings conversion less predictable during execution.
Vaccine And Inhaler Market Pressure
Pressure across major commercial franchises creates a drag on portfolio growth even as newer medicines expand. Shingrix faces China ordering and inventory challenges, while inhaler pricing and competition can constrain revenue quality and margin durability.
GlaxoSmithKline News
GS71 FAQ
What was GlaxoSmithKline’s price range in the past 12 months?
What is GlaxoSmithKline’s market cap?
When is GlaxoSmithKline’s upcoming earnings report date?
How were GlaxoSmithKline’s earnings last quarter?
Is GlaxoSmithKline overvalued?
Does GlaxoSmithKline pay dividends?
What is GlaxoSmithKline’s EPS estimate?
How many shares outstanding does GlaxoSmithKline have?
What happened to GlaxoSmithKline’s price movement after its last earnings report?
Which hedge fund is a major shareholder of GlaxoSmithKline?
What is the TipRanks Smart Score and how is it calculated?
GlaxoSmithKline Stock Smart Score
Company Description
GlaxoSmithKline
GSK plc is a global pharmaceutical and healthcare company, deeply involved in the research, development, production, and commercialization of a diverse range of medicinal and wellness products. Its operations span the United Kingdom, the United States, and numerous other international markets. The company structures its operations across four primary divisions: Pharmaceuticals, Pharmaceutical R&D, Vaccines, and Consumer Healthcare. Within its Pharmaceuticals segment, GSK provides treatments addressing a wide array of therapeutic areas. These include respiratory conditions, HIV, immuno-inflammatory diseases, oncology, viral infections, central nervous system disorders, cardiovascular and urogenital health, metabolic imbalances, bacterial infections, and dermatological issues. The Consumer Healthcare division offers products across categories such as wellness, oral hygiene, nutritional supplements, and skin health. These consumer offerings come in a variety of formats, including oral dosage forms (e.g., tablets, syrups, lozenges, gummies, soft chews, effervescents), topical applications (e.g., gels, creams, patches, lip balms), nasal sprays, and a comprehensive range of oral hygiene products (e.g., toothpastes, mouthwashes, denture care items), alongside other specialized formulations like infant drops and wipes. GSK actively engages in various collaborative ventures. Its collaboration agreements include partnerships with 23andMe, Lyell Immunopharma, Inc., Novartis, Sanofi SA, Surface Oncology, Progentec Diagnostics, Inc., Alector, Inc., and CureVac AG. Additionally, the company maintains strategic alliances with IDEAYA Biosciences, Inc. and Vir Biotechnology, Inc. Originally established in 1715, the company operated under the name GlaxoSmithKline plc until its rebranding to GSK plc in May 2022. Its corporate headquarters are situated in Brentford, United Kingdom.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Luke Victor Miels
- Employees
- 66,841
- Website
- www.gsk.com
- Address
- 79 New Oxford Street, London, GL, WC1A 1DG, GB
GlaxoSmithKline (GS71) Earnings & Revenues
GS71 Earnings Call
Earnings Call SentimentPositive
The call was strongly positive overall. GSK reported solid Q3 sales, operating profit, specialty-medicine growth, cash generation, launch progress, and a significant acceleration in phase III development. The company also reaffirmed 2026 guidance and highlighted encouraging clinical and commercial momentum across oncology, respiratory, HIV, hepatitis B, vaccines, and business development. The main negatives were higher restructuring charges, sharply increased R&D and interest costs, foreign-exchange headwinds, vaccine and inhaler-market pressure, Shingrix inventory and China destocking, and unresolved analysis around the four-monthly APRETUDE formulation. These challenges were meaningful but were outweighed by the breadth of the reported operational and pipeline progress.
View all CH:GS71 earnings summariesGS71 Stock 12 Month Forecast
Average Price Target
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 4 | 2 | 7 |
| Technical Analysis | 0 | 0 | 1 |
| Moving Averages | 4 | 2 | 6 |